Funds › Nantahala Capital Management, LLC
Nantahala Capital Management, LLC
13F for Q3 2026, filed Nov 13, 2026. 143 positions worth $3.2B.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Latest report
Q3 2026
filed Nov 13, 2026
Reported value
$3.2B
−$2.9B (47.5%) vs Q2 2026
Positions
143
131 in Q2 2026
Top 10 share
15.8%
of reported value
CheckedEach line's price per share is checked against other managers' reports of the same stock. Unit mix-ups are corrected. Reports no fix can rescue are left out.
Clean
prices match other managers' reports
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Nantahala Capital Management, LLC in the latest 13F quarter?
Using 13F.ai, how has Nantahala Capital Management, LLC's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Nantahala Capital Management, LLC's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q3 2026
Largest first. Common shares only; puts and calls are under All positions.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | BVS Bioventus Inc. | 6.42M | $87.5M | 2.8% | -46.5% | 13F ↗ |
| 2 | TBBK The Bancorp, Inc. | 1.47M | $70.6M | 2.2% | -40.9% | 13F ↗ |
| 3 | EOLS Evolus, Inc. | 6.24M | $50.0M | 1.6% | -44.3% | 13F ↗ |
| 4 | PTON Peloton Interactive, Inc. | 9.04M | $45.1M | 1.4% | -11.5% | 13F ↗ |
| 5 | ETON Eton Pharmaceuticals, Inc. | 875,507 | $45.1M | 1.4% | -62.8% | 13F ↗ |
| 6 | HGV Hilton Grand Vacations Inc. | 1.28M | $44.2M | 1.4% | -38.2% | 13F ↗ |
| 7 | AMRX Amneal Pharmaceuticals, Inc. | 2.12M | $42.6M | 1.3% | -53.4% | 13F ↗ |
| 8 | LBRX LB Pharmaceuticals Inc | 1.07M | $41.2M | 1.3% | -49.0% | 13F ↗ |
| 9 | SVRA Savara, Inc. | 7.14M | $36.8M | 1.2% | -48.9% | 13F ↗ |
| 10 | FOSL Fossil Group, Inc. | 5.51M | $36.2M | 1.1% | -50.0% | 13F ↗ |
| 11 | RARE Ultragenyx Pharmaceutical Inc. | 2.34M | $35.2M | 1.1% | New | 13F ↗ |
| 12 | AVTX Avalo Therapeutics, Inc. | 2.14M | $32.8M | 1.0% | -42.5% | 13F ↗ |
| 13 | MDXG MiMedx Group, Inc | 6.91M | $32.2M | 1.0% | -27.5% | 13F ↗ |
| 14 | ABEO Abeona Therapeutics Inc. | 5.41M | $28.4M | 0.9% | -47.3% | 13F ↗ |
| 15 | ESTA Establishment Labs Holdings Inc. | 440,556 | $28.3M | 0.9% | -34.4% | 13F ↗ |
| 16 | TITN Titan Machinery Inc. | 1.14M | $26.3M | 0.8% | -49.8% | 13F ↗ |
| 17 | ADMA ADMA Biologics Inc | 2.59M | $26.0M | 0.8% | -45.1% | 13F ↗ |
| 18 | FOXF Fox Factory Holding Corp. | 1.40M | $25.8M | 0.8% | -46.5% | 13F ↗ |
| 19 | DSGR Distribution Solutions Group, Inc. | 733,684 | $25.6M | 0.8% | -25.8% | 13F ↗ |
| 20 | FULC Fulcrum Therapeutics, Inc. | 6.58M | $24.3M | 0.8% | -40.0% | 13F ↗ |
| 21 | XTNT Xtant Medical Holdings, Inc. | 68.39M | $24.3M | 0.8% | -50.0% | 13F ↗ |
| 22 | GOGO Gogo Inc. | 11.21M | $24.1M | 0.8% | -35.5% | 13F ↗ |
| 23 | AURA Aura Biosciences, Inc. | 3.81M | $23.9M | 0.8% | -35.5% | 13F ↗ |
| 24 | REGN Regeneron Pharmaceuticals, Inc. | 31,141 | $23.6M | 0.7% | New | 13F ↗ |
| 25 | JACK Jack In The Box Inc. | 1.73M | $22.9M | 0.7% | -49.9% | 13F ↗ |
| 26 | RMR The RMR Group Inc. | 1.25M | $22.7M | 0.7% | -45.4% | 13F ↗ |
| 27 | HLF Herbalife Ltd. | 1.85M | $22.4M | 0.7% | -16.7% | 13F ↗ |
| 28 | IRD Opus Genetics, Inc. | 4.57M | $22.1M | 0.7% | -25.4% | 13F ↗ |
| 29 | ZVRA Zevra Therapeutics, Inc. | 1.96M | $21.5M | 0.7% | -45.4% | 13F ↗ |
| 30 | AVR Anteris Technologies Global Corp. | 2.76M | $21.4M | 0.7% | -59.2% | 13F ↗ |
| 31 | INSP Inspire Medical Systems, Inc. | 293,034 | $20.3M | 0.6% | -45.6% | 13F ↗ |
| 32 | ABVX Abivax SA · ADR | 198,745 | $19.7M | 0.6% | -25.7% | 13F ↗ |
| 33 | AGMB AgomAb Therapeutics NV · ADR | 1.75M | $19.4M | 0.6% | -44.3% | 13F ↗ |
| 34 | RDNW RideNow Group, Inc. | 3.44M | $18.9M | 0.6% | -47.5% | 13F ↗ |
| 35 | RYAM Rayonier Advanced Materials Inc. | 2.24M | $17.8M | 0.6% | -34.1% | 13F ↗ |
| 36 | VOR Vor Biopharma Inc. | 931,644 | $17.8M | 0.6% | -44.9% | 13F ↗ |
| 37 | TNGX Tango Therapeutics, Inc. | 707,136 | $17.6M | 0.6% | -29.4% | 13F ↗ |
| 38 | BCRX BioCryst Pharmaceuticals, Inc. | 2.10M | $17.5M | 0.6% | -44.7% | 13F ↗ |
| 39 | MLYS Mineralys Therapeutics, Inc. | 689,841 | $17.3M | 0.5% | -58.0% | 13F ↗ |
| 40 | GERN Geron Corporation | 13.87M | $17.1M | 0.5% | -43.3% | 13F ↗ |
| 41 | KROS Keros Therapeutics, Inc. | 1.49M | $17.0M | 0.5% | -47.2% | 13F ↗ |
| 42 | BNTC Benitec Biopharma Inc. | 1.68M | $16.8M | 0.5% | -43.6% | 13F ↗ |
| 43 | OBX Obsidian Therapeutics, Inc. | 1.20M | $16.5M | 0.5% | New | 13F ↗ |
| 44 | JCAP Jefferson Capital, Inc. | 825,607 | $15.8M | 0.5% | -45.0% | 13F ↗ |
| 45 | ADCT ADC Therapeutics SA | 12.58M | $15.3M | 0.5% | -49.0% | 13F ↗ |
| 46 | CWH Camping World Holdings, Inc. | 2.98M | $14.9M | 0.5% | -41.6% | 13F ↗ |
| 47 | JANX Janux Therapeutics, Inc. | 857,334 | $14.8M | 0.5% | -47.1% | 13F ↗ |
| 48 | PLNT Planet Fitness, Inc. | 343,638 | $14.5M | 0.5% | -38.4% | 13F ↗ |
| 49 | VSTM Verastem, Inc. | 1.78M | $14.3M | 0.5% | -75.2% | 13F ↗ |
| 50 | USNA USANA Health Sciences, Inc. | 988,543 | $14.3M | 0.5% | -39.0% | 13F ↗ |
Showing the top 50 of 143 positions. Premium lists every position, plus puts and calls.
Changes since Q2 2026
32 new, 0 added to, 111 trimmed, 20 exited, 0 unchanged. By estimated dollars.
New positions (32)
| RARE Ultragenyx Pharmaceutical Inc. | 2.34M | New | $35.2M |
| REGN Regeneron Pharmaceuticals, Inc. | 31,141 | New | $23.6M |
| OBX Obsidian Therapeutics, Inc. | 1.20M | New | $16.5M |
| RACC Research Alliance Corporation III | 1.10M | New | $11.9M |
| ATTO Attovia Therapeutics, Inc. | 561,180 | New | $9.6M |
| iShares Tr Etf | 34,449 | New | $9.6M |
| SVC Service Properties Trust | 1.39M | New | $8.9M |
| ENTX Entera Bio Ltd. | 3.00M | New | $8.7M |
| DYN Dyne Therapeutics, Inc. | 382,438 | New | $6.2M |
| DMRA Damora Therapeutics, Inc. · Comm Stk | 278,000 | New | $5.9M |
Added to (0)
None this quarter.
Trimmed (111)
| BVS Bioventus Inc. | 6.42M | -46.5% | -$76.1M |
| ETON Eton Pharmaceuticals, Inc. | 875,507 | -62.8% | -$76.0M |
| IMAX Imax Corporation | 151,497 | -88.5% | -$63.8M |
| TBBK The Bancorp, Inc. | 1.47M | -40.9% | -$48.9M |
| AMRX Amneal Pharmaceuticals, Inc. | 2.12M | -53.4% | -$48.8M |
| VSTM Verastem, Inc. | 1.78M | -75.2% | -$43.4M |
| EOLS Evolus, Inc. | 6.24M | -44.3% | -$39.7M |
| LBRX LB Pharmaceuticals Inc | 1.07M | -49.0% | -$39.6M |
| FOSL Fossil Group, Inc. | 5.51M | -50.0% | -$36.2M |
| SVRA Savara, Inc. | 7.14M | -48.9% | -$35.2M |
Exited (20)
| QURE uniQure N.V. | 911,320 | Exited | -$42.0M |
| ITGR Integer Holdings Corporation | 222,604 | Exited | -$20.8M |
| Fractyl Health Inc | 22.58M | Exited | -$17.9M |
| AMLX Amylyx Pharmaceuticals, Inc. | 973,368 | Exited | -$17.5M |
| Damora Therapeutics Inc | 556,000 | Exited | -$14.5M |
| RH Rh | 73,372 | Exited | -$12.1M |
| TRAX First Tracks Biotherapeutics, Inc. · Ord Shs *A* | 500,000 | Exited | -$10.1M |
| Service Pptys Tr Com Sh Ben Int | 5.32M | Exited | -$9.0M |
| CHYM Chime Financial, Inc. | 344,238 | Exited | -$7.0M |
| RLYB Rallybio Corporation | 376,844 | Exited | -$6.0M |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
All positions
Search, sort and filter every position, with puts and calls on their own tab. Premium plan.
Every position, puts and calls. Part of Premium.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Any two quarters side by side. Part of Premium.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q3 2026.
Filings
| Filing | ||||||
|---|---|---|---|---|---|---|
| Q3 2026 | Nov 13, 2026 | 13F-HR | 169 | $3.2B | Current | SEC ↗ |
| Q2 2026 | Aug 19, 2026 | 13F-HR/A (new holdings) | 155 | $3.0B | Current | SEC ↗ |
| Q2 2026 | Aug 14, 2026 | 13F-HR | 152 | $3.0B | Current | SEC ↗ |
| Q1 2026 | May 15, 2026 | 13F-HR | 152 | $2.7B | Current | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | 13F-HR | 153 | $3.0B | Current | SEC ↗ |
| Q3 2025 | Nov 14, 2025 | 13F-HR | 153 | $2.9B | Current | SEC ↗ |
| Q2 2025 | Aug 14, 2025 | 13F-HR | 158 | $2.6B | Current | SEC ↗ |
| Q1 2025 | May 15, 2025 | 13F-HR | 145 | $2.5B | Current | SEC ↗ |
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer